dry eyes; infection after hit by truck / Wound infection; right leg started to get red / become bright red / looked at her leg and it was pinkish / leg went red again / diagnosed with Cellulitis; non-serious cut on right leg; infection after hit by truck / Passenger in motor vehicle accident; staphyloccus infection; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient. Other Case identifier(s): 22K-163-4433870-00 (private).  A 64-year-old female patient received BNT162b2 (BNT162B2), on 05Apr2021 as dose 2, single (Batch/Lot number: unknown) at the age of 64 years intramuscular for covid-19 immunisation. The patient's relevant medical history included: "Non-Tobacco User" (unspecified if ongoing); "Abstains from Alcohol" (unspecified if ongoing); "Penicillin Allergy manifested by Rash" (unspecified if ongoing), notes: Penicillin Allergy manifested by Rash; "Penicillin Allergy manifested by Rash" (unspecified if ongoing), notes: Penicillin Allergy manifested by Rash; "rheumatoid arthritis" (unspecified if ongoing). Concomitant medication(s) included: HUMIRA subcutaneous taken for rheumatoid arthritis, start date: Jan2021, stop date: 2022; NARDIL; METHOTREXATE; PRAMIPEXOLE; KLONOPIN; LITHIUM CARBONATE; METFORMIN; VALTREX; CEPHALEXIN ANHYDROUS. Vaccination history included: BNT162b2 (First dose, Route of Admin: Intramuscular), administration date: 08Mar2021, when the patient was 64-year-old, for COVID-19 immunization. The following information was reported: ROAD TRAFFIC ACCIDENT (medically significant) with onset 07May2021, outcome "unknown", described as "infection after hit by truck / Passenger in motor vehicle accident"; SKIN LACERATION (medically significant) with onset 07May2021, outcome "recovered", described as "non-serious cut on right leg"; STAPHYLOCOCCAL INFECTION (medically significant) with onset May2021, outcome "recovered", described as "staphyloccus infection"; CELLULITIS (medically significant) with onset 16May2021, outcome "recovered", described as "right leg started to get red / become bright red / looked at her leg and it was pinkish / leg went red again / diagnosed with Cellulitis"; DRY EYE (medically significant), outcome "unknown", described as "dry eyes"; WOUND INFECTION (medically significant), outcome "not recovered", described as "infection after hit by truck / Wound infection". The events "non-serious cut on right leg", "infection after hit by truck / passenger in motor vehicle accident" and "right leg started to get red / become bright red / looked at her leg and it was pinkish / leg went red again / diagnosed with cellulitis" required emergency room visit. Therapeutic measures were taken as a result of skin laceration, dry eye, road traffic accident, wound infection, staphylococcal infection, cellulitis. Clinical course of events: The patient experienced the following after administration of the second dose of BNT162b2: non-serious cut on right leg, dry eyes, got an infection after hit by truck, and Staphyloccus infection. The patient has other concomitant therapy of Penicillin. On unknown date, the patient experienced dry eyes. In May2021, the patient experienced Staphyloccus infection. On 07May2021, the patient experienced cut on right leg and got an infection after hit by truck. On unknown dates, cut on right leg and Staphyloccus infection resolved. The patient had an accident on 07May2021where she was hit by a truck. She noted her right leg started to get red on 16May2021 and had become bright red on 19May2021. She went to the emergency room on 20May2021. On 06Jul2022 her doctor looked at her leg and it was pinkish. She was prescribed an antibiotic as precaution. On 22Jul2022, her leg went red again. She went to the emergency room on 26Jul2022 and was diagnosed with Cellulitis. She was prescribed another antibiotic. She mentioned she finished the antibiotic on 03Aug2022. It was unknown if patient was enrolled in a COVID-19 Vaccine Trial. The patient was treated with Doxycycline. The patient was given with Pfizer BioNTech COVID-19 Vaccine (Tozinameran) dose 3, single (first booster), intramuscularly on 31Aug2021.  The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.